Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKUE8O)

• Drug Name: RP5063 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 2	[1]
Alzheimer disease	8A20	Phase 1	[2]
Attention deficit hyperactivity disorder	6A05.Z	Phase 1	[2]
Bipolar disorder	6A60	Phase 1	[2]
Major depressive disorder	6A70.3	Phase 1	[2]
Parkinson disease	8A00.0	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMKUE8O

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[4]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[5]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[5]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[7]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[8]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[9]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[10]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[10]
Pfizer 10	DM6ER9L	Female sexual arousal dysfunction	HA01.1	Phase 1	[11]

Drug(s) Targeting Dopamine D4 receptor (D4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[5]
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[12]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
L-745,870	DMTGR25	Psychotic disorder	6A20-6A25	Phase 2	[13]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[14]
ABT-724	DMDQVY4	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[15]
Lu-35138	DMQ7A35	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[16]
NGD-94-4	DMZ9WLO	Schizophrenia	6A20	Discontinued in Phase 1	[17]
PD-165167	DMD0GB4	Schizophrenia	6A20	Preclinical	[14]
SPI-376	DMC1WAJ	Schizophrenia	6A20	Preclinical	[14]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[18]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[19]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[20]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[4]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[21]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[22]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[23]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[24]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[25]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[26]

Drug(s) Targeting Serotoninnorepinephrinedopamine reuptake (SNDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
OPC-64005	DMIK2AD	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[27]
Brilaroxazine	DM90J3J	Idiopathic pulmonary fibrosis	CB03.4	Phase 1	[28]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[29]
Haloperidol	DM96SE0	Delirium		Approved	[30]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[31]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[32]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[33]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[34]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[35]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[36]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[37]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[20]

Drug(s) Targeting Histamine H1 receptor (H1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[38]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[39]
Azelastine	DMXTMBJ	Allergic conjunctivitis	9A60.02	Approved	[40]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[41]
Cinnarizine	DM7U5QJ	Meniere disease	AB31.0	Approved	[42]
Diphenhydramine	DMKQTBA	Hyperemesis gravidarum		Approved	[40]
Doxepin	DMPI98T	Anxiety		Approved	[43]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[40]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[44]
Desloratadine	DM56YN7	Allergic rhinitis	CA08.0	Approved	[45]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[5]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[46]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[47]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[48]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[4]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[49]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[50]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[51]
Treximet	DMU54QB	Migraine	8A80	Approved	[10]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[52]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[53]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[54]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[55]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[55]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[56]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[56]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[57]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[58]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[59]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Antagonist	[3]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Partial agonist	[2]
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Partial agonist	[2]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[3]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Partial agonist	[2]
Dopamine D4 receptor (D4R)	TTE0A2F	DRD4_HUMAN	Partial agonist	[2]
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Partial agonist	[2]
Serotoninnorepinephrinedopamine reuptake (SNDR)	TT8G3Z7	NOUNIPROTAC	Partial agonist	[2]

References

• [1] ClinicalTrials.gov (NCT01490086) RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [7] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [11] Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
• [12] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [13] Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
• [14] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [15] Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
• [17] I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
• [18] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [19] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [20] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [21] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [22] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [24] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [25] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [26] Clinical pipeline report, company report or official report of Lundbeck.
• [27] Clinical pipeline report, company report or official report of Otsuka Pharmaceutical.
• [28] Clinical pipeline report, company report or official report of Reviva Pharmaceuticals
• [29] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [30] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [31] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [32] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [33] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [35] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [36] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [37] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [38] Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
• [39] Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
• [40] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [41] Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
• [42] Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
• [43] Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
• [44] Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
• [45] Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
• [46] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [47] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [48] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [49] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [50] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [51] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [52] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [53] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [54] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [55] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [56] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [57] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [58] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [59] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.